Minimal change disease and focal segmental glomerulosclerosis

被引:0
|
作者
Osterholt, Thomas [1 ]
Benzing, Thomas [1 ]
Brinkkoetter, Paul Thomas [1 ]
机构
[1] Uniklin Koln, Klin Innere Med Nephrol Rheumatol Diabetol & Allge, Kerpener Str 62, D-50937 Cologne, Germany
来源
NEPHROLOGIE | 2025年 / 20卷 / 01期
关键词
FSGS; MCD; Minimal change disease; Focal segmental glomerulosclerosis; Review; CONGENITAL NEPHROTIC SYNDROME; FINNISH TYPE; ADULTS; FSGS;
D O I
10.1007/s11560-024-00814-2
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are among the most common causes of nephrotic syndrome. Histologically both diseases are defined as podocytopathies characterized by the fusion of podocyte foot processes which are visible under electron microscopy. While the exact pathogenesis was unclear for a long time, accumulating evidence suggests that anti-nephrin antibodies play a central role in many cases of MCD. The genesis of FSGS is complex. The disease is characterized by the irreversible loss of podocytes and a resulting focal sclerosis in the glomerulus. The differentiation between primary, secondary and genetic forms of these diseases is crucial for the selection of treatment as only primary forms generally require immunosuppression. Several therapeutic approaches are available for treatment, including steroids, calcineurin inhibitors (CNI), such as tacrolimus and mycophenolate mofetil (MMF). The FSGS and MCD differ in their response rates to treatment, with FSGS generally having a poorer prognosis. In the future, targeted therapies will gain increasing importance, especially in genetically related variants of FSGS. Overall, the treatment of MCD and FSGS remains a challenge and requires a customized and carefully coordinated treatment based on individual patient characteristics.
引用
收藏
页码:18 / 25
页数:8
相关论文
共 50 条
  • [21] Potential Urine Proteomic Biomarkers for Focal Segmental Glomerulosclerosis and Minimal Change Disease
    Chebotareva, Natalia, V
    Vinogradov, Anatoliy
    Brzhozovskiy, Alexander G.
    Kashirina, Daria N.
    Indeykina, Maria I.
    Bugrova, Anna E.
    Lebedeva, Marina
    Moiseev, Sergey
    Nikolaev, Evgeny N.
    Kononikhin, Alexey S.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (20)
  • [22] In situ evaluation of podocytes in patients with focal segmental glomerulosclerosis and minimal change disease
    da Silva, Crislaine Aparecida
    Goncalves dos Reis Monteiro, Maria Luiza
    Araujo, Liliane Silvano
    Urzedo, Monise Gini
    Rocha, Lenaldo Branco
    dos Reis, Marlene Antonia
    Machado, Juliana Reis
    PLOS ONE, 2020, 15 (11):
  • [23] Comparative differential proteomic analysis of minimal change disease and focal segmental glomerulosclerosis
    Vanessa Pérez
    Dolores López
    Ester Boixadera
    Meritxell Ibernón
    Anna Espinal
    Josep Bonet
    Ramón Romero
    BMC Nephrology, 18
  • [24] Nephrotic syndrome in minimal change disease (kidneys), focal segmental glomerulosclerosis and focal mesangioproliferative glomerulonephritis
    Voznesenskaya, TS
    Sergeeva, TV
    TERAPEVTICHESKII ARKHIV, 2002, 74 (06) : 31 - 33
  • [25] Pathophysiology of minimal change nephrotic syndrome and focal segmental glomerulosclerosis
    Cho, Min Hyun
    Hong, Eun Hee
    Lee, Tae Ho
    Ko, Cheol Woo
    NEPHROLOGY, 2007, 12 : S11 - S14
  • [26] Rituximab Treatment for Relapsing Minimal Change Disease and Focal Segmental Glomerulosclerosis: A Systematic Review
    Kronbichler, Andreas
    Kerschbaum, Julia
    Fernandez-Fresnedo, Gema
    Hoxha, Elion
    Kurschat, Christine E.
    Busch, Martin
    Bruchfeld, Annette
    Mayer, Gert
    Rudnicki, Michael
    AMERICAN JOURNAL OF NEPHROLOGY, 2014, 39 (04) : 322 - 330
  • [27] A newly established clinical registry of minimal change disease and focal and segmental glomerulosclerosis in Germany
    Voelker, Linus A.
    Ehren, Rasmus
    Grundmann, Franziska
    Benzing, Thomas
    Weber, Lutz T.
    Brinkkoetter, Paul T.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 (12) : 1983 - 1986
  • [28] Urinary Peptide Profiling to Differentiate between Minimal Change Disease and Focal Segmental Glomerulosclerosis
    Perez, Vanessa
    Ibernon, Meritxell
    Lopez, Dolores
    Cruz Pastor, Maria
    Navarro, Maruja
    Navarro-Munoz, Maribel
    Bonet, Josep
    Romero, Ramon
    PLOS ONE, 2014, 9 (01):
  • [29] A SYSTEMATIC REVIEW OF RITUXIMAB TREATMENT FOR RELAPSING MINIMAL CHANGE DISEASE AND FOCAL SEGMENTAL GLOMERULOSCLEROSIS
    Kronbichler, Andreas
    Kerschbaum, Julia
    Mayer, Gert
    Rudnicki, Michael
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 190 - 190
  • [30] Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis
    Garin, Eduardo H.
    Mu, Wei
    Arthur, John M.
    Rivard, Christopher J.
    Araya, Carlos E.
    Shimada, Michiko
    Johnson, Richard J.
    KIDNEY INTERNATIONAL, 2010, 78 (03) : 296 - 302